


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Presently amended) ~~The present invention provides a~~ A compound of formula (I), or a pharmaceutically acceptable salt thereof, or solvate thereof, or a solvate of a salt thereof:



wherein

Z is CR^4R^5 , $\text{C}(\text{O})$ or $\text{CR}^4\text{R}^5-\text{Z}^+$, wherein R^4 and R^5 are CH_2 ;

Z^+ is C_{1-4} -alkylene, C_{2-4} -alkenylene or $\text{C}(\text{O})\text{NH}$;

R^+ represents a C_1 - C_{12} -alkyl group optionally substituted by one or more substituents independently selected from cyano, hydroxyl, C_1 - C_6 -alkoxy, C_1 - C_6 -alkylthio, C_{3-7} -cycloalkyl, C_1 - C_6 -alkoxycarbonyl and phenyl (itself optionally substituted by one or more of halogen, nitro, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, phenyl(C_1 - C_6 -alkyl), C_1 - C_6 -alkoxy, C_1 - C_6 -haloalkoxy, $\text{S}(\text{O})_2(\text{C}_1$ - C_6 -alkyl), $\text{C}(\text{O})\text{NH}_2$, carboxy or C_1 - C_6 -alkoxycarbonyl); or

R^+ represents C_2 - C_6 -alkenyl optionally substituted by phenyl (itself optionally substituted by one or more of halogen, nitro, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, phenyl(C_1 - C_6 -alkyl), C_1 - C_6 -alkoxy, C_1 - C_6 -haloalkoxy, $\text{S}(\text{O})_2(\text{C}_1$ - C_6 -alkyl), $\text{C}(\text{O})\text{NH}_2$, carboxy or C_1 - C_6 -alkoxycarbonyl); or

R^1 represents a 3- to 14-membered saturated or unsaturated ring system which optionally comprises up to two ring carbon atoms that form carbonyl groups and which optionally further comprises up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, wherein the ring system is optionally substituted by one or more substituents independently selected from: halogen, cyano, nitro, oxo, hydroxyl, C_1 - C_8 alkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6

haloalkyl, C₁₋₆ alkoxy(C₁₋₆ alkyl), C₃₋₇ cycloalkyl(C₁₋₆ alkyl), C₁₋₆ alkylthio(C₁₋₆ alkyl), C₁₋₆ alkylcarbonyloxy(C₁₋₆ alkyl), C₁₋₆ alkylS(O)₂(C₁₋₆ alkyl), aryl(C₁₋₆ alkyl), heterocyclyl(C₁₋₆ alkyl), arylS(O)₂(C₁₋₆ alkyl), heterocyclylS(O)₂(C₁₋₆ alkyl), aryl(C₁₋₆ alkyl)S(O)₂, heterocyclyl(C₁₋₆ alkyl)S(O)₂, C₂₋₆ alkenyl, C₁₋₆ alkoxy, carboxy-substituted C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ hydroxyalkoxy, C₁₋₆ alkylcarboxy-substituted C₁₋₆ alkoxy, aryloxy, heterocycloxy, C₁₋₆ alkylthio, C₃₋₇ cycloalkyl(C₁₋₆ alkylthio), C₃₋₆ alkynylthio, C₁₋₆ alkylcarbonylamino, C₁₋₆ haloalkylcarbonylamino, SO₃H, -NR⁷R⁸, -C(O)NR²³R²⁴, S(O)₂NR¹⁸R¹⁹, S(O)₂R²⁰, R²⁵C(O), carboxyl, C₁₋₆ alkoxy-carbonyl, aryl and heterocyclyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by one or more of halogen, oxo, hydroxy, nitro, cyano, C₁₋₆ alkyl, C₁₋₆ haloalkyl, phenyl(C₁₋₆ alkyl), C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, S(O)₂(C₁₋₆ alkyl), C(O)NH₂, carboxy or C₁₋₆ alkoxy-carbonyl;

m is 0 or 1;

~~Q represents an oxygen or sulphur atom or a group NR⁹, C(O), C(O)NR⁹, NR⁹C(O) or CH=CH;~~

n is 0, 1, 2, 3, 4, 5 or 6 provided that when n is 0, then m is 0;

each R² and R³ independently represents a hydrogen atom or a C₁₋₄ alkyl group, or (CR²R³)_n represents C₃₋₇ cycloalkyl optionally substituted by C₁₋₄ alkyl;

T represents a group NR¹⁰, C(O)NR¹⁰, NR¹¹C(O)NR¹⁰ or C(O)NR¹⁰NR¹¹, wherein R¹⁰ is H;

~~X¹, X², X³ and X⁴ are, independently, CH₂, CHR¹² (wherein each R¹² is, independently, C₁₋₄ alkyl or C₃₋₇ cycloalkyl(C₁₋₄ alkyl)) or C=O; or, when they are CHR¹², the R¹² groups of X¹ and X³ or X⁴, or, X² and X³ or X⁴ join to form a two or three atom chain which is CH₂CH₂, CH₂CH₂CH₂, CH₂OCH₂ or CH₂SCH₂; provided always that at least two of X¹, X², X³ and X⁴ are CH₂;~~

R⁴ and R⁵ each independently represent a hydrogen atom or a C₁₋₄ alkyl group;

~~R⁶ is aryl or heterocyclylphenyl, both optionally substituted by one or more of: halogen, cyano, nitro, oxo, hydroxyl, C₁₋₈ alkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy(C₁₋₆ alkyl), C₃₋₇ cycloalkyl(C₁₋₆ alkyl), C₁₋₆ alkylthio(C₁₋₆ alkyl), C₁₋₆ alkylcarbonyloxy(C₁₋₆ alkyl), C₁₋₆ alkylS(O)₂(C₁₋₆ alkyl), aryl(C₁₋₆ alkyl), heterocyclyl(C₁₋₆ alkyl), arylS(O)₂(C₁₋~~


C₆ alkyl), heterocyclylS(O)₂(C₁-C₆ alkyl), aryl(C₁-C₆ alkyl)S(O)₂, heterocyclyl(C₁-C₆ alkyl)S(O)₂, C₂-C₆ alkenyl, C₁-C₆ alkoxy, carboxy-substituted C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ hydroxyalkoxy, C₁-C₆ alkylcarboxy-substituted C₁-C₆ alkoxy, aryloxy, heterocyclyoxy, C₁-C₆ alkylthio, C₃-C₇ cycloalkyl(C₁-C₆ alkylthio), C₃-C₆ alkynylthio, C₁-C₆ alkylcarbonylamino, C₁-C₆ haloalkylcarbonylamino, SO₃H, -NR¹⁶R¹⁷, -C(O)NR²¹R²², S(O)₂NR¹³R¹⁴, S(O)₂R¹⁵, R²⁶C(O), carboxyl, C₁-C₆ alkoxy-carbonyl, aryl and heterocyclyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by one or more of halogen, nitro, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl, phenyl(C₁-C₆ alkyl), C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, S(O)₂(C₁-C₆ alkyl), C(O)NH₂, carboxy or C₁-C₆ alkoxy-carbonyl; R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹³, R¹⁴, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²¹, R²², R²³ and R²⁴ are, independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₄ alkyl) or phenyl(C₁-C₆ alkyl); and, R¹⁵ and R²⁰ are, independently, C₁-C₆ alkyl, C₁-C₆ hydroxyalkyl, C₃-C₆ cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₄ alkyl) or C₁-C₆ alkyl optionally substituted by phenyl; R²⁵ and R²⁶ are, independently, C₁-C₆ alkyl or phenyl (optionally substituted by one or more of halogen, nitro, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl, phenyl(C₁-C₆ alkyl), C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, S(O)₂(C₁-C₆ alkyl), C(O)NH₂, carboxy or C₁-C₆ alkoxy-carbonyl); ~~or a pharmaceutically acceptable salt thereof, or solvate thereof, or a solvate of a salt thereof; provided that when T is C(O)NR¹⁰ and R¹ is optionally substituted phenyl then n is not 0.~~

2-4. (Cancelled)


5. A compound as defined in any one of Examples 1 to 416.

6. (Presently amended) A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises:

~~(a) when n is at least 1, the CR²R³ group attached directly to T is CHR³ and T is NR¹⁰; reacting a compound of general formula~~




wherein n' is 0 or an integer from 1 to 3 and $\text{R}^1, \text{R}^2, \text{R}^3, m$ and Q are as defined in formula (I), with a compound of general formula




or a salt thereof, wherein $\text{X}^1, \text{X}^2, \text{X}^3, \text{X}^4, \text{Z}, \text{R}^6$ and R^{10} are as defined in formula (I), in the presence of a reducing agent; or

(b) — when n is at least 1, the CR^2R^3 group attached directly to T is $\text{C}(\text{C}_1\text{-C}_4\text{-alkyl})_2$ and T is NR^{10} ; reacting a compound of general formula




wherein n' is 0 or an integer from 1 to 3, $\text{R}^{2'}$ and $\text{R}^{3'}$ each independently represent a $\text{C}_1\text{-C}_4$ alkyl group, and $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^{10}, m$ and Q are as defined in formula (I), with a compound of general formula




wherein $\text{X}^1, \text{X}^2, \text{X}^3, \text{X}^4, \text{Z}$ and R^6 are as defined in formula (I), in the presence of a reducing agent; or

(ea) when T is C(O)NR¹⁰, reacting a compound of general formula




wherein R¹, R², R³, Q, m and n are as defined in formula (I), with a compound of formula (III)




wherein X¹, X², X³, X⁴, Z, R⁶ and R¹⁰ are as defined in formula (I),
 or a salt thereof as defined in (a) above; or

~~(d) when m is 1 and Q is NR⁹, reacting a compound of general formula (VII), R⁺-L⁺,
 wherein L⁺ represents a leaving group (e.g. a halogen atom) and R⁺ is as defined in formula (I),
 with a compound of general formula~~




~~or a salt thereof, wherein n, T, X¹, X², X³, X⁴, Z, R², R³, R⁶ and R⁹ are as defined in formula (I);
 or~~

(eb) when at least one of R⁴ and R⁵ represents a hydrogen atom, reacting a compound of
 general formula




or a salt thereof, wherein R^1 , R^2 , R^3 , Q , m , n , X^1 , X^2 , X^3 , X^4 and T are as defined in formula (I), with a compound of general formula (X), $R^6 - C(O) - R^{20}$, wherein R^{20} represents a hydrogen atom or a C_1 - C_4 alkyl group and R^6 is as defined in formula (I), in the presence of a reducing agent; or

(~~f~~c) reacting a compound of formula (IX) as defined in (~~e~~)~~(b)~~ above, with a compound of general formula




wherein L^2 represents a leaving group (e.g. a halogen atom) and Z and R^6 are as defined in formula (I); ~~or~~

~~(g) when T is NR^{10} , reacting a compound of general formula~~




~~wherein L^3 represents a leaving group (e.g. a halogen atom) and R^1 , R^2 , R^3 , m , n and Q are as defined in formula (I), with a compound of formula (III) or a salt thereof as defined in (a) above; or~~

~~(h) when T is $NHC(O)NR^{10}$, reacting a compound of general formula~~



~~wherein R^1 , R^2 , R^3 , Q , m and n are as defined in formula (I), with a compound of formula (III) or a salt thereof as defined in (a) above; or~~

(i) when T is C(O)NH, Z is CH₂, n is 1, R² and R³ are hydrogen or C₁-C₄ alkyl and Q is oxygen or sulphur, reacting a compound of formula (XIV):



wherein Hal is a suitable halogen, R², R³, X¹, X², X³, X⁴, Z and R⁶ are as defined in formula (I), with R¹OH or R¹SH in the presence of a suitable base;


and optionally after (a), (b), or (c), (d), (e), (f), (g), (h) or (i) forming a pharmaceutically acceptable salt or solvate of the compound of formula (I) obtained.

7. (Presently amended) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as ~~claimed in any one of claims claim 1 to 4~~ in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

8. (Presently amended) A process for the preparation of a pharmaceutical composition as claimed in claim 7 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as ~~claimed in any one of claims claim 1 to 4~~ with a pharmaceutically acceptable adjuvant, diluent or carrier.

9-10. (Cancelled)

11. (Presently Amended) A method of treating ~~an inflammatory disease~~ asthma in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or solvate thereof, or a solvate of a salt thereof, ~~as defined claim 10.~~



wherein

Z is CR⁴R⁵, wherein R⁴ and R⁵ are CH₂;

R¹ represents a 3- to 14-membered saturated or unsaturated ring system which comprises up to two ring carbon atoms that form carbonyl groups and which further comprises up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, wherein the ring system is optionally substituted by one or more substituents independently selected from: halogen, cyano, nitro, oxo, hydroxyl, C₁-C₈ alkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ haloalkyl, C₁₋₆ alkoxy(C₁-C₆ alkyl), C₃-C₇ cycloalkyl(C₁-C₆ alkyl), C₁-C₆ alkylthio(C₁-C₆ alkyl), C₁-C₆ alkylcarbonyloxy(C₁-C₆ alkyl), C₁-C₆ alkylS(O)₂(C₁-C₆ alkyl), aryl(C₁-C₆ alkyl), heterocyclyl(C₁-C₆ alkyl), arylS(O)₂(C₁-C₆ alkyl), heterocyclylS(O)₂(C₁-C₆ alkyl), aryl(C₁-C₆ alkyl)S(O)₂, heterocyclyl(C₁-C₆ alkyl)S(O)₂, C₂-C₆ alkenyl, C₁-C₆ alkoxy, carboxy-substituted C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ hydroxyalkoxy, C₁-C₆ alkylcarboxy-substituted C₁-C₆ alkoxy, aryloxy, heterocycliloxy, C₁-C₆ alkylthio, C₃-C₇ cycloalkyl(C₁-C₆ alkylthio), C₃-C₆ alkynylthio, C₁-C₆ alkylcarbonylamino, C₁-C₆ haloalkylcarbonylamino, SO₃H, -NR⁷R⁸, -C(O)NR²³R²⁴, S(O)₂NR¹⁸R¹⁹, S(O)₂R²⁰, R²⁵C(O), carboxyl, C₁-C₆ alkoxy-carbonyl, aryl and heterocyclyl;

wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by one or more of halogen, oxo, hydroxy, nitro, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl, phenyl(C₁-C₆ alkyl), C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, S(O)₂(C₁-C₆ alkyl), C(O)NH₂, carboxy or C₁-C₆ alkoxy-carbonyl;

m is 0;

n is 2;

each R² and R³ independently represents a hydrogen atom or a C₁-C₄ alkyl group, or (CR²R³)_n represents C₃-C₇ cycloalkyl optionally substituted by C₁-C₄ alkyl;

T represents a group C(O)NR¹⁰;

X¹, X², X³ and X⁴ are, independently, CH₂;

R⁴ and R⁵ each independently represent a hydrogen atom or a C₁-C₄ alkyl group;

R⁶ is phenyl optionally substituted by one or more of: halogen, cyano, nitro, oxo, hydroxyl, C₁-C₈ alkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ haloalkyl, C₁₋₆ alkoxy(C₁-C₆ alkyl), C₃-C₇ cycloalkyl(C₁-C₆ alkyl), C₁-C₆ alkylthio(C₁-C₆ alkyl), C₁-C₆ alkylcarbonyloxy(C₁-C₆ alkyl), C₁-C₆ alkylS(O)₂(C₁-C₆ alkyl), aryl(C₁-C₆ alkyl), heterocyclyl(C₁-C₆ alkyl), arylS(O)₂(C₁-C₆ alkyl), heterocyclylS(O)₂(C₁-C₆ alkyl), aryl(C₁-C₆ alkyl)S(O)₂, heterocyclyl(C₁-C₆ alkyl)S(O)₂, C₂-C₆ alkenyl, C₁-C₆ alkoxy, carboxy-substituted C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ hydroxyalkoxy, C₁-C₆ alkylcarboxy-substituted C₁-C₆ alkoxy, aryloxy, heterocycliloxy, C₁-C₆ alkylthio, C₃-C₇ cycloalkyl(C₁-C₆ alkylthio), C₃-C₆ alkynylthio, C₁-C₆ alkylcarbonylamino, C₁-C₆ haloalkylcarbonylamino, SO₃H, -NR¹⁶R¹⁷, -C(O)NR²¹R²², S(O)₂NR¹³R¹⁴, S(O)₂R¹⁵, R²⁶C(O), carboxyl, C₁-C₆ alkoxy-carbonyl, aryl and heterocyclyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by one or more of halogen, nitro, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl, phenyl(C₁-C₆ alkyl), C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, S(O)₂(C₁-C₆ alkyl), C(O)NH₂, carboxy or C₁-C₆ alkoxy-carbonyl;

R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹³, R¹⁴, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²¹, R²², R²³ and R²⁴ are, independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₄ alkyl) or phenyl(C₁-C₆ alkyl); and,

R¹⁵ and R²⁰ are, independently, C₁-C₆ alkyl, C₁-C₆ hydroxyalkyl, C₃-C₆ cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₄ alkyl) or C₁-C₆ alkyl optionally substituted by phenyl;

R²⁵ and R²⁶ are, independently, C₁-C₆ alkyl or phenyl (optionally substituted by one or more of halogen, nitro, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl, phenyl(C₁-C₆ alkyl), C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, S(O)₂(C₁-C₆ alkyl), C(O)NH₂, carboxy or C₁-C₆ alkoxy-carbonyl).